Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
芎蛭通络胶囊 is a Traditional Chinese Medicine (TCM) capsule formulation primarily indicated for the treatment of sequelae of stroke during the recovery period, particularly for patients presenting with qi deficiency and blood stasis syndrome. Its therapeutic actions include replenishing qi, promoting blood circulation, and unblocking collaterals. The drug is composed of multiple Chinese medicinal herbs and animal-derived substances, including Ligusticum chuanxiong (川芎) and Hirudo (水蛭), among others. Pharmacologically, it is reported to reduce infarct area, inhibit platelet aggregation, decrease blood viscosity, delay carotid thrombosis, and inhibit inflammatory factors like Interleukin-6 (IL-6) and Tumor necrosis factor alpha (TNF-α), thereby inhibiting neuronal apoptosis and improving neurological function. It aims to improve symptoms such as hemiplegia, limb numbness, facial distortion, speech difficulty, and body fatigue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 芎蛭通络胶囊.